NL-OMON31060已完成不适用
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA) - CV149-208
Bristol-Myers Squibb0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects with one or more sirolimus or paclitaxel drug-eluting stents who are coming to the end of their 12 months of clopidogrel (75 mg daily) treatment.
- •2. Subjects receiving low dose ASA.
- •3. Subjects receiving a statin.
- •4. Current medication regimen (including ASA and statins) must have been stable for three (3) months, i.e. no initiation of new prescription medication or change in dosage of any previously initiated medication within three (3) months of entering this study.
- •5. Subjects with no clinical history of diabetes mellitus.
排除标准
- •1. Subjects with a clinical history of diabetes mellitus.
- •2. History of alcohol or substance abuse within the past 12 months.
- •3. Any condition the Investigator believes would interfere with evaluation of the subject or which could put the subject at undue risk.
- •4. Uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic
- •>100mmHg) at screening.
- •5. Intolerance or contraindication to ASA or statins.
- •6. Current use or use within the past 3 months of oral anticoagulants or dipyridamole or oral glucocorticoids.
研究者
相似试验
进行中（未招募）
不适用
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate theDiscontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) onInflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA). - DECADESBiomarkers of inflammation and platelet activationMedDRA version: 9.1Level: LLTClassification code 10058542Term: Anti-platelet antibodyEUCTR2007-000713-11-GBBristol Myers Squibb International Corporation105
进行中（未招募）
不适用
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate theDiscontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) onInflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA).Revised Protocol 02 to incorporate protocol amendments 01 and 02 - DECADESBiomarkers of inflammation and platelet activationMedDRA version: 9.1Level: LLTClassification code 10058542Term: Anti-platelet antibodyEUCTR2007-000713-11-DEBristol Myers Squibb International Corporation105
进行中（未招募）
1 期
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate theDiscontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) onInflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA). - DECADESBiomarkers of inflammation and platelet activationMedDRA version: 9.1Level: LLTClassification code 10058542Term: Anti-platelet antibodyEUCTR2007-000713-11-FRBristol Myers Squibb International Corporation105
进行中（未招募）
1 期
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate theDiscontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) onInflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA). - DECADESBiomarkers of inflammation and platelet activationMedDRA version: 9.1Level: LLTClassification code 10058542Term: Anti-platelet antibodyEUCTR2007-000713-11-NLBristol Myers Squibb International Corporation105
尚未招募
Unknown
Post-market clinical follow-up study for flowable gelatin haemostatic matrix kit in real-world patients to stop bleeding during surgeryCTRI/2024/06/068248Aegis Lifesciences Private Limited